Premium
In vitro and in vivo Bone‐Forming Activity of Saururus chinensis Extract
Author(s) -
Moon SeongHee,
Choi SikWon,
Park SangJoon,
Ryu ShiYong,
Hwang KyuSeok,
Kim CheolHee,
Kim Seong Hwan
Publication year - 2015
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5349
Subject(s) - chemistry , in vivo , bone morphogenetic protein 2 , osteoblast , alkaline phosphatase , osteoclast , mesenchymal stem cell , noggin , bone resorption , pharmacology , in vitro , bone morphogenetic protein , microbiology and biotechnology , medicine , biochemistry , endocrinology , biology , enzyme , gene
Bone is maintained by osteoclast‐mediated resorption and osteoblast‐mediated formation. Recently, anti‐osteoporotic activity of Saururus chinensis extract (SCE) and anti‐osteoclastogenic activity of its components have been reported, but the effect of SCE on bone formation has not been studied well. Therefore, in this study, we investigated whether Saururus chinensis SCE exhibits in vitro osteogenic and in vivo bone‐forming activity. extract strongly enhanced the bone morphogenetic protein (BMP)‐2‐stimulated induction of alkaline phosphatase, an early phase biomarker of osteoblast differentiation, in bi‐potential mesenchymal progenitor C2C12 cells. In vitro osteogenic activity of SCE was accompanied by enhanced expression of BMP‐2, BMP‐4, BMP‐7 and BMP‐9 mRNA. In addition, a pharmacological inhibition study suggested the involvement of p38 activation in the osteogenic action of SCE. Moreover, the BMP dependency and the involvement of p38 activation in the osteogenic action of SCE were confirmed by the treatment of noggin, an antagonist of BMP. Saururus chinensis extract also exhibited to induce runt‐related transcription factor 2 activation at the high concentration. Furthermore, the in vivo osteogenic activity of SCE was confirmed in zebrafish and mouse calvarial bone formation models, suggesting the possibility of its use for bone formation. In conclusion, we suggested that in vivo anti‐osteoporotic activity of SCE could be because of its dual action in bone, anti‐osteoclastogenic and anabolic activity. Copyright © 2015 John Wiley & Sons, Ltd.